Home » ImmunoGen Gets $2 Million Milestone Fee
ImmunoGen Gets $2 Million Milestone Fee
March 17, 2005
Cancer drug developer ImmunoGen has said that French drug company sanofi-aventis Group initiated clinical testing with huMy9-6-DM4 -- the anti-CD33 Tumor-Activated Prodrug compound that it licensed from ImmunoGen -- triggering a $2 million milestone payment to the company. HuMy9-6-DM4 is in development for the treatment of acute myeloid leukemia. The compound combines an engineered antibody, which binds to the CD33 target found on acute myeloid leukemia cancer cells, and a potent cell-killing agent.
Yahoo News (http://biz.yahoo.com/ap/050317/immunogen_sanofi_aventis_1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct